GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises ...

Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and ...

Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...

The firm says its “bullish” key opinion leader checks indicated the “disruptive potential” of iDose across the U.S. glaucoma treatment landscape over the next several years. The checks ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are ...

As we pass the 1-year anniversary of our controlled launch of iDose TR, I could not be more pleased with our team's execution of our plans for this first-of-its-kind intracameral procedural ...

During the fourth quarter, GKOS’ glaucoma franchise witnessed revenue growth, driven by its iStent portfolio, coupled with growing contributions from iDose TR. Establishing permanent J-code ...

Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three ...

The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose ...

In other recent news, Glaukos Corporation has reported promising developments regarding its iDose TR product, with clinical trials demonstrating sustained efficacy in reducing intraocular pressure ...